Could Start-Up Adagio’s COVID-19 Antibody Have A Fighting Chance?
Executive Summary
The company announced a $336m series C round, six months after it raised an $80m series B, to support development of an easily administered treatment ADG20.
You may also be interested in...
Coronavirus Update: Moderna Donates More Doses, Booster Shot Shows Efficacy
Novavax said it would start shipping supplies of its vaccine to Europe starting in late 2021, while Vaxart delayed the start of its Phase II study due to issues with Emergent BioSolutions. Meanwhile, Roche India received an EUA for Regeneron's antibody cocktail
EMA Reviews GSK/Vir’s COVID-19 Antibody To Support Early Use By Member States
After preliminary discussions with its pandemic task force, the European Medicines Agency has begun reviewing GSK/Vir Biotechnology’s promising COVID-19 treatment to help EU national competent authorities make evidence-based decisions on its possible early use.
Merck’s COVID-19 Therapeutic Development Path Gets A Little Harder
After backing off of MRK-7110 for hospitalized patients the company’s focus is on the oral antiviral molnupiravir for outpatients – which would be a huge win, but the drug has yet to fully prove itself in the clinic.